Starling Oncology, Inc. (STLNW) community

STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 6/30

$0.03+0.00 (+10.87%)

Close on Oct 30, 2026Market cap $665.51MP/E –Yield –

Community

Notes and questions about Starling Oncology from other investors

No posts about STLNW yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Starling Oncology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is STLNW.

Compare: STLNW vs CCM · STLNW vs SBC · STLNW vs LFMD · STLNW vs TDOC · STLNW vs AUNA

Revenue growth38.4% · median -2.4%

Operating margin-4.4% · median -6.6%

Net margin-6.2% · median 0.1%

Company	Revenue	Growth
TDOC	$2.47B	-2.4%
STLNW	$587.24M	+38.4%
SBC	$175.17M	-6.9%
LFMD	$164.70M	+3.8%
CCM	–	–
AUNA	–	–

Company

Next earnings (est.): Nov 12, 2026, during market hours
Exchange: Nasdaq
Industry: Services-Offices & Clinics of Doctors of Medicine
Fiscal year ends: December 31
Employees: 641
Auditor: BDO USA, P.C.
SEC CIK: 1799191

Advertisement
300 × 250